App-Quantinova.ai

Serum GGTP as an HCC prognostic marker in patients with both low and high AFP levels.

Brian I. Carr - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

N/A

Role of metronomic capecitabine in advanced hepatocellular carcinoma.

Abdul Mateen - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Capecitabine

Sorafenib (S) in HCC: Is there a role for starting at a total daily dose of 400mg?

Olugbenga Olanrele Olowokure - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

N/A

Sorafenib

Can alfa-fetoprotein response to sorafenib predict for response and overall survival in hepatocellular carcinoma?

Humdum Pasha Durrani - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Alfa-fetoprotein

A pilot study for cellular detection of circulating tumor cells and disseminated tumor cells of patients with hepatocellular carcinoma.

Nozomi Minagawa - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

N/A

Circulating tumor cell capture in hepatocellular carcinoma (HCC).

Holly Rochefort - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Alfa-fetoprotein

Apatinib in Chinese patients with advanced hepatocellular carcinoma: A phase II randomized, open-label trial.

Shukui Qin - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Apatinib

Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Analysis of patients with elevated ?-fetoprotein (AFP) from the randomized phase III REACH study.

Andrew X. Zhu - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Ramucirumab

Treatment outcome of patients with intermediate- and poor-prognosis metastatic testicular cancer in the 2000s: A multicenter experience in Japan.

Takahiro Kojima - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Testicular cancer

N/A

Prevalence of hypogonadism in previously treated germ cell tumor patients.

Trent James Miller - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Germ cell tumor

Human chorionic gonadotropin

SIOPEL 6: A multicenter open-label randomized phase III trial of the efficacy of sodium thiosulphate (STS) in reducing ototoxicity in patients receiving cisplatin (Cis) monotherapy for standard-risk hepatoblastoma (SR-HB).

Rudolf Maibach - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Hepatoblastoma

sodium thiosulfate

Evaluation of a multi-level, multi-parameter detection method for digestive system cancer diagnosis.

Yefan Zhang - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Alfa-fetoprotein

Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Analysis of REACH pts by Child-Pugh (CP) score.

Andrew X. Zhu - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Ramucirumab

A retrospective analysis of patients with metastatic germ cell tumor (GCT) treated at Indiana University (IU) from 2000 to 2012.

Kimberly Ku - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Germ cell tumor

N/A

Serum tumor markers among patients (pts) with nasopharyngeal carcinoma (NPC): A single institution experience.

Justin D. Kaner - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Nasopharyngeal carcinoma

Alkaline phosphatase

Serum tumor marker utilization in patients with advanced solid tumors.

Melissa Kate Accordino - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Anti-tumor efficacy in SIOPEL 6: A multi-centre open label randomised phase III trial of the efficacy of sodium thiosulphate (STS) in reducing ototoxicity in patients receiving cisplatin (Cis) monotherapy for standard risk hepatoblastoma (SR-HB).

Penelope Rachel Brock - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Hepatoblastoma

sodium thiosulfate

CTCs as early biomarkers of primary liver cancer in the patients with liver diseases.

Alexandre Tavartkiladze - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Hepatic fibrosis

N/A

Development of hepatocellular carcinoma in a HBeAg-negative chronic hepatitis B patient without cirrhosis under the long-term virological suppression with lamivudine plus adefovir therapy

E. Gunal - International Congress on Infectious Diseases (ICID) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Alfa-fetoprotein

Randomized dose comparison phase II study of the oral transforming growth factor-beta (TGF-) receptor I kinase inhibitor LY2157299 monohydrate (LY) in patients with advanced hepatocellular carcinoma (HCC).

Sandrine J. Faivre - American Society of Clinical Oncology (ASCO) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

LY2157299

Filters

486 Abstracts